ANGELA GANN: Open Payments
NPI 1841683695 · SHEFFIELD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,967 in 127 payments from 20 companies in 2025. Trend: 2023 $2,056 · 2024 $3,688 · 2025 $2,967
Food & beverage: $2,888Education: $79
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $402 |
| Insmed, Inc. | 14 | $347 |
| GlaxoSmithKline, LLC. | 23 | $342 |
| GENZYME CORPORATION | 12 | $320 |
| Regeneron Healthcare Solutions, Inc. | 10 | $279 |
| Merck Sharp & Dohme LLC | 7 | $162 |
| Lilly USA, LLC | 9 | $158 |
| Inspire Medical Systems, Inc. | 4 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $138 |
Products named: DUPIXENT, Arikayce, NUCALA, AIRSUPRA, ZERBAXA, BREZTRI, INSPIRE, GLASSIA.
Industry payments across AL — which companies pay providers there.
